Cell-cycle targeted therapies

Lancet Oncology

Volumn 5, Issue 1, 2004, Pages 27-36

  Swanton, Charles ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTIDIARRHEAL AGENT; CARBOPLATIN; CYCLIN D; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; FLAVOPIRIDOL; GROWTH FACTOR; IRINOTECAN; MESSENGER RNA; PACLITAXEL; PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN P18; PROTEIN P19; PROTEIN P21; PROTEIN P27; PROTEIN P57; RAPAMYCIN; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR E2F; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG;

ARTERY THROMBOSIS; BINDING AFFINITY; CANCER GROWTH; CANCER THERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL DIVISION; CELL GROWTH; CELLULAR DISTRIBUTION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVITY; ESOPHAGUS CANCER; GENE DELETION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GROWTH REGULATION; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INFLAMMATION; LUNG CANCER; LUNG TOXICITY; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RETINOBLASTOMA; REVIEW; STOMACH CANCER; VEIN THROMBOSIS;

EID: 0347917093     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01321-4     Document Type: Review

References (74)

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-28.
2. Pardee A. A restricition point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 1974; 71: 1286-1290.
3. Cooper S. Reappraisal of serum starvation, the restriction point, G0 and G1 phase arrest points. FASEB J 2003; 17: 333-40.
4. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
5. Kamijo T, Zindy F, Roussel MF, et al. Tumour suppression at the mouse INK4a locus mediated by the alternative reading frame product of p19ARF. Cell 1997; 91: 649-59.
6. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001; 413: 83-86.
7. Sharpless NE, Bardeesy N, Lee K-H, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumourigenesis. Nature 2001; 413: 86-91.
8. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995; 375: 503-06.
9. Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281-84.
10. Ruas M, Peters G. p16ink4a/CDKN2A tumour suppressor and its relatives. BBA Rev Cancer 1998; 1378/2: F115-17.
11. LaBaer J, Garrett MD, Stevenson LF, et al. New functional activities for the p21 family of cdk inhibitors. Genes Dev 1997; 11: 847-62.
12. Card GL, Knowles P, Laman H, et al. Crystal structure of a gamma-herpesvirus cyclin-cdk complex. EMBO J 2000; 19: 2877-88.
13. Swanton C, Mann DJ, Fleckenstein B, et al. Viral cyclin/cdk6 complexes evade inhibition by cdk inhibitory proteins. Nature 1997; 390: 184-87.
14. Chen Y-N, Sharma S, Ramsey T, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999; 96: 4325-29.
15. Sheaff R, Groudine M, Gordon M, et al. Cdk2 is a regulator of p27kip1. Genes Dev 1997; 11: 1464-78.
16. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3: 222-25.
17. Loda M, Cukor B, Tam S, et al. Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231-34.
18. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227-30.
19. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8: 1153-60.
20. Shin I, Yakes M, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27kip1 at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8: 1145-52.
21. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8: 1136-44.
22. Zhou BP, Liao Y, Xia W, et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neuoverexpressing cells. Nat Cell Biol 2001; 3: 245-52.
23. Blagosklonny MV. Are p27 and p21 cytoplasmic oncoproteins? Cell Cycle 2002; 1: 391-93.
24. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1: 222-31.
25. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18: 753-61.
26. Harbour JW, Luo RX, Del Santi A, et al. cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98: 859-69.
27. Ezhevsky SA, Ho A, Becker-Hapak M, et al. Differential regulation of retinoblastoma tumor suppressor protein by G1 cyclin-dependent kinase complexes in vivo. Mol Cell Biol 2001; 21: 4773-84.
28. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-26.
29. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3 beta regulates cyclin D1 proteolysis and subcellular localisation. Genes Dev 1998; 12: 3499-11.
30. Lin X, Nelson P, Gelman IH. SSeCKS, a major protein kinase C substrate with tumour suppressor activity, regulates G1-S progression by controlling the expression and cellular compartmentalization of cyclin D. Mol Cell Biol 2000; 20: 7259-72.
31. Cheng M, Olivier P, Diehl JA, et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999; 18: 1571-83.
32. Sugimoto M, Martin N, Wilks DP, et al. Activation of cyclin D1-kinase in murine fibroblasts lacking both p21(Cip1) and p27(Kip1). Oncogene 2002; 21: 8067-74.
33. Sugimoto M, Nakamura T, Ohtani N, et al. Regulation of CDK4 activity by a novel CDK4-binding protein, p34SEI-1. Genes Dev 1999; 13: 3027-33.
34. McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA 1999; 96: 5382-87.
35. Peters G, Fantl V, Smith R, et al. Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res Treat 1995; 33: 125-35.
36. Wang TC, Cardiff RD, Zukerberg L, et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669-71.
37. Bowe DB, Kenney NJ, Adereth Y, Maroulakou IG. Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E. Oncogene 2002; 21: 291-98.
38. Strohmaier H, Spruck CH, Kaiser P, et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413: 268-69.
39. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347: 1566-74.
40. van de Vijver MJ, Yudong DH, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2068.
41. Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16: 2986-99.
42. Thomas J, Cleary J, Tutsch K, et al. Phase I clinical and pharmacokinetic trial of flavopiridol. Proc Am Assoc Cancer Res 1997; 38: 222 (abstr).
43. Stadler WM, Vogelzang NJ, Amato R, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor in metastatic renal cancer: a University of Chicago Phase II Consortium study. J Clin Oncol 2000; 18: 371-75.
44. Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001; 7: 1590-99.
45. Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19: 1985-92.
46. Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of Flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002; 20: 4074-82.
47. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997; 57: 3375-80.
48. Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumours. J Clin Oncol 2002; 20: 2157-70.
49. Shah MA, Kortmansky J, Gonen M, et al. A phase I/pharmacological study of weekly sequential irinotecan and flavopiridol. Proc Am Soc Clin Oncl 2002: 373 (abstr).
50. Gries J-M, Kasimis B, Schwarzenberger P, et al. Phase I study of HMR1275 (flavopiridol) in non-small cell lung cancer (NSCLC) patients after 24hr IV administration in combination with paclitaxel and carboplatin. Proc Am Soc Clin Oncl 2002: 372 (abstr).
51. Chen X, Lowe M, Keyomarsi K. UCN-01 mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene 1999; 18: 5691-702.
52. Mack PC, Gandara DR, Bowen C, et al. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clin Cancer Res 1999; 5: 2596-604.
53. Patel V, Lahusen T, Leethanakul C, et al. Antitumour activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(kip1). Clin Cancer Res 2002; 8: 3549-60.
54. Busby EC, Leistritz DF, Abraham RT, et al. The radiosensitising agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000; 60: 2108-12.
55. Graves PR, Yu L, Schwarz JK, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000; 275: 5600-05.
56. Zhao B, Bower MJ, McDevitt PJ, et al. Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 2002; 277: 46609-15.
57. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002; 21: 1727-38.
58. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001; 19: 2319-33.
59. Drexler HCA. Activation of the cell death program by inhibition ofproteosome function. Proc Natl Acad Sci USA 1997; 94: 855-60.
60. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteosome inhibitor PS-341 in patients with refractory hematological malignancies. J Clin Oncol 2002; 20: 4420-27.
61. Richardson PG, Berenson J, Irwin D. Phase II trial of PS-341, a novel proteosome inhibitor, alone or in combination with dexamethasone, in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood 2001; 98: 774 (abstr).
62. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteosome inhibition. Leukemia 2000; 14: 1276-83.
63. Owa T, Yoshino H, Okauchi T, et al. Discovery of novel antitumour sulfonamides targeting G1 phase of the cell cycle. J Med Chem 1999; 42: 3789-99.
64. Ozawa Y, Sugi NH, Nagasu T, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer 2001; 38: 2275-82.
65. Dittrich C, Dumez H, Calvert H et al. Phase I and pharmacokinetic study of E7070, a novel chlorindoyl-sulfonamide inhibiting the activation of cdk2 and cyclin E. Clin Cancer Res 2000; 6: 4529s (abstr).
66. Droz JP, Roch H, Zanetta Sea. Phase I trial of five-days continuous infusion E7070 (N(3-chloro-7-indoly)-1,4-benzene-disulfonamide) in patients with solid tumors. Proc Am Assoc Cancer Res 2000; 41: 609 (abstr).
67. Punt CJA, Fumoleau P, van de Walle B, et al. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times 5 schedule in patients with solid tumours: a study by the EORTC-Early Clinical Studies Group (ECSG). Ann Oncol 2001; 12: 1289-93.
68. Raymond E, ten Bokkel Huinink WW, Taieb J, et al. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell cycle inhibitor, administered as a one-hour infusion every three weeks. J Clin Oncol 2002; 20: 3508-21.
69. Talbot D, Norbury C, Slade M, et al. A Phase II and pharmacodynamic study of E7070 in patients with non-small cell lung cancer (NSCLC) who have failed platinum-based chemotherapy. Proc Am Soc Clin Oncol 2002; 1306 (abstr).
70. Mainwaring PN, Van Cutsem E, Van Laethem J-L, et al. A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy. Proc Am Soc Clin Oncol 2002; 611 (abstr).
71. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92: 1210-16.
72. Sandor V, Robbins AR, Robey R, et al. FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs 2000; 11: 445-54.
73. Sandor V, Senderowicz A, Mertins S, et al. P21-dependent g(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000; 83: 817-25.
74. Saito A, Yamashita T, Mariko Y, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592-597.